Revenue and margins have been highly volatile, with gross margin ranging from 80.0% to 100.0% but operating margin swinging from 65.7% in 2026Q2 to -118.2% in 2026Q3, indicating that profitability depends on lumpy collaboration recognition rather than a stable operating base.
Arvinas, Inc. (ARVN) annual income statement — 10-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Sales/Revenue | 275.3M | 262.6M | 263.4M | 78.5M | 131.4M | 53.6M | 25.9M | 42.98M | 14.32M | 7.58M | 6.67M |
| Revenue Growth % | -11.85% | -0.3% | 235.54% | -40.26% | 145.15% | 106.95% | -39.73% | 200.03% | 89% | 13.64% | - |
| Cost of Goods Sold | 11.4M | 5.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 1.98% | - | - | - | - | - | - | - | - | - |
| Gross Profit | 263.9M | 257.4M | 263.4M | 78.5M | 131.4M | 53.6M | 25.9M | 42.98M | 14.32M | 7.58M | 6.67M |
| Gross Margin % | 95.86% | 98.02% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | -2.28% | 235.54% | -40.26% | 145.15% | 106.95% | -39.73% | 200.03% | 89% | 13.64% | - |
| Operating Expenses | 293.3M | 372.3M | 513.6M | 480M | 394.6M | 242M | 146.7M | 94.5M | 58.13M | 32.34M | 23.14M |
| OpEx % of Revenue | - | 141.77% | 194.99% | 611.47% | 300.3% | 451.49% | 566.41% | 219.89% | 405.8% | 426.7% | 346.95% |
| Selling, General & Admin | 76.2M | 89.4M | 165.4M | 100.3M | 79.6M | 61.6M | 38.3M | 27.31M | 12.93M | 3.55M | 3.2M |
| SG&A % of Revenue | - | 34.04% | 62.79% | 127.77% | 60.58% | 114.93% | 147.88% | 63.54% | 90.28% | 46.79% | 47.93% |
| Research & Development | 220.6M | 282.9M | 348.2M | 379.7M | 315M | 180.4M | 108.4M | 67.19M | 45.19M | 28.79M | 19.94M |
| R&D % of Revenue | - | 107.73% | 132.19% | 483.69% | 239.73% | 336.57% | 418.53% | 156.35% | 315.51% | 379.91% | 299.03% |
| Other Operating Expenses | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 102.73K | 0 | 0 |
| Operating Income | -29.4M | -114.9M | -250.2M | -401.5M | -263.2M | -188.4M | -120.8M | -51.52M | -43.8M | -24.76M | -16.47M |
| Operating Margin % | -10.68% | -43.75% | -94.99% | -511.47% | -200.3% | -351.49% | -466.41% | -119.89% | -305.8% | -326.7% | -246.95% |
| Operating Income Growth % | - | 54.08% | 37.68% | -52.55% | -39.7% | -55.96% | -134.45% | -17.63% | -76.9% | -50.34% | - |
| EBITDA | -25.9M | -109.7M | -243.6M | -394.8M | -255M | -182.4M | -116.7M | -49.27M | -43.1M | -24.41M | -16.03M |
| EBITDA Margin % | -9.41% | -41.77% | -92.48% | -502.93% | -194.06% | -340.3% | -450.58% | -114.65% | -300.87% | -322.12% | -240.41% |
| EBITDA Growth % | 73.16% | 54.97% | 38.3% | -54.82% | -39.8% | -56.3% | -136.85% | -14.33% | -76.53% | -52.27% | - |
| D&A (Non-Cash Add-back) | 3.5M | 5.2M | 6.6M | 6.7M | 8.2M | 6M | 4.1M | 2.25M | 706K | 347.39K | 436.33K |
| EBIT | -25.2M | -80.5M | -198.3M | -366.4M | -261.6M | -190.9M | -120.8M | -70.21M | -41.42M | -24M | -14.37M |
| Net Interest Income | 26.3M | 22M | 54.8M | 38.8M | 12M | 1.7M | 3.52M | 4.5M | 2.41M | 151.03K | 360.37K |
| Interest Income | 26.3M | 22M | 54.8M | 38.8M | 12M | 1.8M | 3.59M | 4.6M | 2.47M | 201.39K | 427.77K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 100K | 65K | 100K | 57.44K | 50.36K | 67.4K |
| Other Income/Expense | 20.6M | 34.4M | 51.9M | 35.1M | 1.6M | -2.6M | 1.5M | -18.79M | 2.32M | 711.06K | 2.03M |
| Pretax Income | -8.8M | -80.5M | -198.3M | -366.4M | -261.6M | -191M | -119.3M | -70.3M | -41.48M | -24.05M | -14.44M |
| Pretax Margin % | -3.2% | -30.65% | -75.28% | -466.75% | -199.09% | -356.34% | -460.62% | -163.58% | -289.59% | -317.32% | -216.49% |
| Income Tax | 300K | 300K | 600K | 900K | 20.9M | 0 | 0 | 0 | 0 | 0 | -87.41K |
| Effective Tax Rate % | -3.41% | -0.37% | -0.3% | -0.25% | -7.99% | 0% | 0% | 0% | 0% | 0% | 0.61% |
| Net Income | -9.5M | -80.8M | -198.9M | -367.3M | -282.5M | -191M | -119.3M | -70.29M | -41.48M | -24.05M | -14.35M |
| Net Margin % | -3.45% | -30.77% | -75.51% | -467.9% | -214.99% | -356.34% | -460.62% | -163.56% | -289.59% | -317.32% | -215.18% |
| Net Income Growth % | 83.76% | 59.38% | 45.85% | -30.02% | -47.91% | -60.1% | -69.72% | -69.46% | -72.48% | -67.58% | - |
| Net Income (Continuing) | -9.1M | -80.8M | -198.9M | -367.3M | -282.5M | -191M | -119.3M | -70.3M | -41.48M | -24.05M | -14.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.15 | -1.28 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -1.89 | -1.31 | -1.38 | -7.56 |
| EPS Growth % | 77.78% | 53.79% | 58.16% | -24.67% | -39.01% | -26.49% | -59.79% | -44.27% | 5.07% | 81.75% | - |
| EPS (Basic) | - | -1.28 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -1.89 | -1.31 | -1.38 | -7.56 |
| Diluted Shares Outstanding | 65.4M | 64.9M | 71.9M | 55.5M | 53.2M | 50M | 39.53M | 32.93M | 31.63M | 20.73M | 1.9M |
| Basic Shares Outstanding | 65.4M | 64.9M | 71.9M | 55.5M | 53.2M | 50M | 39.53M | 32.93M | 31.63M | 20.73M | 1.9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ARVN stock.
For fiscal year 2025, Arvinas, Inc. (ARVN) reported total revenue of $262.6M. This represents a 3837.6% increase compared to $6.7M in 2016.
Arvinas, Inc. (ARVN) reported a net loss of $80.8M for the fiscal year ending 2025.
Arvinas, Inc. (ARVN) reported an operating income of $-114.9M, resulting in an operating profit margin of -43.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Arvinas, Inc. (ARVN) generated $257.4M in gross profit for the year, representing a gross profit margin of 98.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Lumpy collaboration revenue dependence
Metrics are mathematically derived from official filings.
Revenue Driven by Lumpy Collaboration Milestones
Based on reported quarterly figures, ARVN revenue swung from $249.7M in 2026Q2 to just $0.5M in 2026Q3, a pattern that signals revenue recognition tied to episodic partnership events rather than recurring demand.
The quarterly series shows no sustained compounding; instead, revenue alternates between large milestone-driven spikes and near-zero quarters. This suggests growth durability is low and that trailing comparisons carry little predictive value. Investors should monitor whether future collaboration milestones reappear at similar scale before extrapolating any trend.
Operating Losses Persist Despite Revenue Peaks
According to reported income statements, R&D expense has remained between roughly $47M and $91M per quarter, and operating income has been negative in most periods, indicating limited operating leverage.
Operating income turns positive only in quarters with outsized revenue, such as 2026Q2 at $164.1M, while the cost base stays largely fixed. This implies that operating results are dominated by the timing of licensing receipts rather than by scalable operating efficiency. The shortfall in operating leverage warrants further investigation into the durability of the cost structure.
Net Income Dependent on Non-Operating Swings
Reported net income tracks operating income closely, but EPS swung from $2.58 in 2026Q2 to -$0.90 in 2026Q1, showing that per-share results remain highly volatile.
Because net income moves in step with lumpy revenue, the quality of reported earnings depends heavily on the recognition timing of partnership payments. Stock-based compensation remains material relative to quarterly operating costs, at $5.9M to $24.7M per quarter, which reduces the economic residual available to shareholders. Investors should treat single-quarter profitability as non-representative.
Cost Base Stable While Revenue Fluctuates
Based on EDBL-style cost reporting, ARVN's R&D spending of $46.9M to $93.7M per quarter has remained the dominant expense, while SG&A has ranged from $12.6M to $75.8M.
R&D accounts for the majority of the cost base in nearly every period, which is consistent with a clinical-stage development model. The SG&A line has been volatile, with a notable spike in 2024Q3, which may reflect non-recurring items, though this cannot be confirmed from the data provided. The absence of a clear downward trend in R&D suggests continued pipeline investment that weighs on near-term margins.
Peak Quarter May Not Reflect Run-Rate
The strongest bear case is that 2026Q2's $249.7M revenue and $164.1M operating income are non-recurring, and that the surrounding quarters show a business still losing money.
Excluding the 2026Q2 spike, ARVN reported operating losses in the majority of the ten quarters shown, and the most recent quarter registered a loss of $59.1M on only $0.5M of revenue. Short-sellers would likely argue that reported profitability reflects one-time licensing income rather than a sustainable commercial model. This interpretation is inferential and should be weighed against any disclosed upcoming milestone or partnership pipeline.